drugset / Trial / NCT02442791

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

NCT02442791

Completed 120 enrolled Jesper Kjaergaard
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Experimental studies and previous clinical trials suggest neuroprotective effects of GLP-1 analogs in various degenerative neurological diseases, and in hypoxic brain injuries in experimental designs. This study is designed as a safety and feasibility study with patients randomized 1:1 to receive GLP-1 analogs immediately after hospital admission after out of hospital cardiac arrest.

Timeline

Start
2014-06
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 17.4 ug

Indications